One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Conformis logo
Conformis CFMS
report update icon

Quarterly report 2023-Q2
added 05-16-2026

Conformis Financial Ratios 2022-2011 | CFMS

Brief overview of Conformis's financial ratios

Ratios are assessed across five available annual reports in the 2018–2022 interval.

The latest available valuation ratios are P/S 0.2x (median 1.05x), P/B 0.23x (median 2x). Valuation is roughly 84.5% below five-year reference levels. The discount may reflect opportunity or higher perceived risk.

Returns on assets and capital are represented by ROE -93.2%, ROA -53.7%, ROCE -85.4%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.

A shorter cycle, from 264.4 days to 165.4 days, indicates faster release of cash from operations.

Valuation takeaway

Conformis trades below its own history, but weak profitability may explain the discount. Low multiples alone do not prove undervaluation.

Annual Financial Ratios Conformis

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-0.3 -1.8 -3.0 -9.2 -7.3 -5.0 -3.6 -3.5 - - - -

P/S

0.2 0.0 1.1 2.5 3.3 2.8 9.6 3.0 - - - -

EPS

-7.0 -0.4 -0.3 -0.4 -0.7 -1.2 -1.4 -2.6 -10.8 -12.0 - -

EV (Enterprise Value)

3.84 M -51.5 M 104 M 79.6 M 82.8 M 87.9 M 190 M 101 M -16.4 M -39.3 M - -

EBITDA per Share

-5.85 0.19 -0.29 -0.33 -0.59 -1.2 -1.28 -2.43 -10.2 -11.4 - -

EV/EBITDA

-0.1 -40.7 -5.0 -3.8 -2.4 -1.7 -3.6 -1.9 0.4 0.9 - -

PEG

0.0 0.03 0.09 0.2 0.19 -0.11 -0.13 0.06 - - - -

P/B

0.2 0.0 6.4 3.1 2.0 1.3 2.2 1.4 - - - -

P/CF

-0.3 -0.5 -4.0 -17.6 -2.9 -1.5 -6.0 -4.1 - - - -

ROE %

-93.16 -2.40 -213.62 -33.24 -27.27 -25.49 -61.23 -40.54 -91.76 -69.44 - -

ROA %

-53.67 -1.66 -33.98 -7.50 -15.67 -12.64 -51.05 -35.92 -64.15 -57.08 - -

ROCE %

-85.42 -2.99 -61.88 -46.07 -74.97 -69.05 -56.98 -38.27 -75.15 -67.15 - -

Current Ratio

2.4 3.2 1.2 1.3 2.4 2.0 6.0 8.8 3.3 5.6 - -

DSO

55.4 32.1 52.0 223.0 218.5 245.2 248.8 65.4 34.5 - - -

DIO

160.3 148.4 128.4 96.9 82.7 77.4 79.7 77.7 43.4 - - -

DPO

50.4 61.3 61.6 46.5 36.8 38.4 35.0 33.7 20.4 - - -

Operating Cycle

215.8 180.5 180.4 319.9 301.2 322.5 328.5 143.2 77.9 - - -

Cash Conversion Cycle

165.4 119.2 118.8 273.4 264.4 284.2 293.5 109.5 57.5 - - -

All numbers in USD currency

Quarterly Financial Ratios Conformis

2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-1.78 -1.32 - -0.08 -0.09 -0.09 - -0.07 0.21 -0.09 -0.08 -0.09 -0.03 -0.14 -0.08 -0.13 -0.11 -0.12 -0.16 -0.12 -0.24 -0.22 -0.27 -0.29 -0.28 -0.4 -0.37 -0.31 -0.34 -0.37 -0.37 -0.45 -2.51 -3.32 -2.83 -2.44 -2.49 -3.04 - - - - - - - - - - - -

EBITDA per Share

-1.43 -1.17 - -0.05 -0.06 -0.08 - -0.05 0.19 -0.06 - -0.05 - -0.1 - -0.06 -0.06 -0.09 - -0.06 -0.16 -0.21 - -0.23 -0.28 -0.38 - -0.25 -0.3 -0.35 - -0.38 -2.23 -3.15 - -2.06 -2.24 - - - - - - - - - - - - -

ROE %

-108.07 -86.08 -64.64 -75.95 -20.84 -12.87 5.77 -52.46 -74.03 -129.57 -214.69 -189.70 -200.54 -200.03 -126.68 -120.71 -94.10 -97.92 -92.87 -91.10 -95.90 -85.02 -86.63 -77.87 -68.14 -62.57 -52.79 -46.67 -45.51 -72.92 -71.28 -85.01 -94.85 -76.46 -24.34 -20.86 -21.16 - - - - - - - - - - - - -

ROA %

-58.65 -51.90 -40.22 -48.45 -11.38 -6.02 6.43 -2.83 -2.33 -28.03 -34.87 -33.11 -37.25 -44.50 -41.59 -49.75 -46.50 -51.02 -50.74 -47.71 -51.05 -46.55 -50.09 -51.40 -50.03 -50.41 -45.58 -41.03 -40.29 -48.31 -47.02 -54.63 -59.37 -55.34 -17.02 -14.59 -14.79 - - - - - - - - - - - - -

ROCE %

-96.52 -75.23 -54.10 -64.01 -19.84 -12.95 4.19 -33.41 -50.70 -160.14 -149.66 -184.09 -168.07 -162.57 -77.70 -92.69 -81.35 -80.43 -58.73 -81.42 -86.80 -85.45 -64.79 -77.11 -66.61 -58.07 -36.33 -46.78 -73.93 -71.70 -59.88 -80.61 -91.27 -9.96 - -20.73 -21.11 - - - - - - - - - - - - -

Current Ratio

1.9 2.2 2.4 2.4 2.7 3.0 3.2 3.7 3.9 2.5 1.2 1.3 1.1 1.2 1.3 1.4 1.7 1.9 2.4 2.0 2.1 2.4 2.0 2.2 2.4 3.3 6.0 7.7 9.1 7.9 8.8 9.3 1.9 8.8 3.3 3.3 3.3 - - - - - - - - - - - - -

DSO

56.9 65.1 - 62.9 58.7 56.4 - 57.1 13.9 55.1 47.8 48.6 38.3 53.4 49.5 57.3 56.5 57.9 51.5 37.6 58.1 58.7 56.7 60.6 61.5 61.9 60.0 65.9 62.8 64.0 55.3 63.3 61.5 74.5 58.5 69.3 37.2 - - - - - - - - - - - - -

DIO

157.1 226.5 - 177.6 150.2 143.5 - 154.7 138.6 154.4 - 141.1 135.2 117.9 - 104.7 92.4 80.6 - 94.2 78.7 72.9 - 91.8 86.4 75.5 - 85.6 81.8 80.9 - 88.4 89.4 93.4 - 95.5 49.4 - - - - - - - - - - - - -

DPO

31.6 49.1 - 70.2 57.2 54.5 - 55.8 51.6 59.1 - 64.1 68.2 64.6 - 41.4 39.5 33.3 - 51.5 47.4 39.0 - 38.6 40.4 36.7 - 23.9 27.2 36.1 - 45.8 39.5 40.5 - 44.9 23.3 - - - - - - - - - - - - -

Operating Cycle

213.9 291.7 - 240.5 208.9 199.9 - 211.8 152.5 209.5 46.5 184.3 175.8 175.8 50.9 172.2 162.0 144.8 54.7 135.6 150.4 139.9 58.0 140.8 133.7 130.5 61.8 156.4 149.5 144.6 71.1 192.1 162.8 167.8 58.5 164.8 86.7 - - - - - - - - - - - - -

Cash Conversion Cycle

182.3 242.5 - 170.3 151.7 145.4 - 156.0 100.9 150.4 46.5 131.1 122.7 117.5 50.9 107.0 98.7 101.1 54.7 101.7 118.9 105.0 58.0 100.6 97.2 96.6 61.8 116.9 112.0 110.4 71.1 153.4 125.0 127.3 58.5 119.9 63.4 - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Conformis, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Orthofix Medical Orthofix Medical
OFIX
$ 9.7 -1.12 % $ 384 M curacaoCuracao
TransMedics Group TransMedics Group
TMDX
$ 71.03 0.41 % $ 2.41 B usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 5.05 1.78 % $ 3.4 M usaUSA
AxoGen AxoGen
AXGN
$ 38.31 0.64 % $ 1.76 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Venus Concept Venus Concept
VERO
- - $ 726 K usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
Butterfly Network Butterfly Network
BFLY
$ 6.78 0.37 % $ 1.68 B usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA
Abiomed Abiomed
ABMD
- - $ 17.2 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Viveve Medical Viveve Medical
VIVE
- -15.35 % $ 1.71 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
ViewRay ViewRay
VRAY
- 1.54 % $ 468 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 47.96 -2.48 % $ 1.49 B usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 9.05 -1.04 % $ 256 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA
Delcath Systems Delcath Systems
DCTH
$ 14.66 1.66 % $ 525 M usaUSA
SeaSpine Holdings Corporation SeaSpine Holdings Corporation
SPNE
- 0.28 % $ 270 M usaUSA
Zynex Zynex
ZYXI
- - $ 21.1 M usaUSA
Medigus Ltd. Medigus Ltd.
MDGS
- 10.28 % $ 55.5 M israelIsrael
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Globus Medical Globus Medical
GMED
$ 81.12 -0.36 % $ 11 B usaUSA
Nemaura Medical Nemaura Medical
NMRD
- -17.8 % $ 2.74 M britainBritain
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 12.07 1.34 % $ 925 M usaUSA
InMode Ltd. InMode Ltd.
INMD
$ 13.77 -1.43 % $ 890 M israelIsrael
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 2.41 1.69 % $ 99 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.12 -4.69 % $ 14.7 M usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 85.76 -0.12 % $ 1.09 B usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 126.54 -0.01 % $ 4.4 B usaUSA
Inogen Inogen
INGN
$ 7.05 -0.77 % $ 188 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 57.98 0.68 % $ 8.8 B usaUSA